SINAGRA, Gianfranco
 Distribuzione geografica
Continente #
NA - Nord America 910
EU - Europa 432
AS - Asia 287
OC - Oceania 3
SA - Sud America 3
AF - Africa 1
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1.637
Nazione #
US - Stati Uniti d'America 903
IT - Italia 139
CN - Cina 122
HK - Hong Kong 92
FI - Finlandia 80
DE - Germania 78
UA - Ucraina 60
SG - Singapore 55
IE - Irlanda 32
GB - Regno Unito 16
CZ - Repubblica Ceca 9
IN - India 9
FR - Francia 6
SE - Svezia 6
CA - Canada 5
BR - Brasile 3
JP - Giappone 3
PH - Filippine 3
MX - Messico 2
NZ - Nuova Zelanda 2
AU - Australia 1
AZ - Azerbaigian 1
BE - Belgio 1
BG - Bulgaria 1
ES - Italia 1
EU - Europa 1
LK - Sri Lanka 1
MT - Malta 1
MU - Mauritius 1
NL - Olanda 1
RU - Federazione Russa 1
SA - Arabia Saudita 1
Totale 1.637
Città #
Ashburn 142
Fairfield 110
Hong Kong 92
Helsinki 70
Woodbridge 66
Chandler 57
Jacksonville 54
Seattle 48
Beijing 46
Wilmington 43
Princeton 40
New York 39
Cambridge 37
Houston 37
Dublin 32
Singapore 30
Romola 27
Ann Arbor 25
Milan 23
Shanghai 22
Brescia 19
Washington 17
Nanjing 16
Dearborn 10
Lappeenranta 10
Brno 9
Los Angeles 9
Hebei 8
San Diego 8
Des Moines 7
Munich 7
Rome 7
Frankfurt am Main 6
Novara 6
Jinan 5
Pune 5
Shenyang 5
Hangzhou 4
Leipzig 4
London 4
Venice 4
North Bergen 3
Quezon City 3
San Francisco 3
Strasbourg 3
São Paulo 3
Toronto 3
Tsukuba 3
Verona 3
Calcinato 2
Castrezzato 2
Chennai 2
Christchurch 2
Costa Masnaga 2
Falkenstein 2
Gavardo 2
Guangzhou 2
Halle 2
Jiaxing 2
Kunming 2
Lancaster 2
Margherita di Savoia 2
Nanchang 2
Naples 2
Ningbo 2
Norwalk 2
Panipat 2
Sandigliano 2
Tianjin 2
West Jordan 2
Acton 1
Arcore 1
Baku 1
Boardman 1
Brembate di Sopra 1
Brussels 1
Cerignola 1
Changsha 1
Chaoyang 1
Chiswick 1
Colombo 1
Como 1
Crotone 1
Eindhoven 1
Esslingen am Neckar 1
Florence 1
Islington 1
Kilburn 1
Lanzhou 1
Magdeburg 1
Markham 1
New Bedfont 1
Orange 1
Prescot 1
Reggio Nell'emilia 1
Richmond 1
Riyadh 1
Salò 1
Sofia 1
Stockholm 1
Totale 1.306
Nome #
Prognostic role of β-blocker selectivity and dosage regimens in heart failure patients. Insights from the MECKI score database 109
Deceptive meaning of oxygen uptake measured at the anaerobic threshold in patients with systolic heart failure and atrial fibrillation 103
Heart failure and anemia: Effects on prognostic variables 101
Prognostic role of atrial fibrillation in patients affected by chronic heart failure. Data from the MECKI score research group 96
Renal function and peak exercise oxygen consumption in chronic heart failure with reduced left ventricular ejection fraction 91
Sex Profile and Risk Assessment With Cardiopulmonary Exercise Testing in Heart Failure: Propensity Score Matching for Sex Selection Bias 91
The metabolic exercise test data combined with Cardiac And Kidney Indexes (MECKI) score and prognosis in heart failure. A validation study 91
ANMCO / FADOI / SIAARTI / SIC / SIMG / SIMI / SIMEU Consensus Document: The clinical-diagnostic and therapeutic pathway of the patient with acute heart failure from home to discharge from the Emergency Room / Emergency Department-Acceptance 66
Sacubitril/Valsartan: Updates and Clinical Evidence for a Disease-Modifying Approach 46
[Palliative inotrope therapy in advanced heart failure: organization and management] 40
Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19) 39
Machine learning for prediction of in-hospital mortality in coronavirus disease 2019 patients: results from an Italian multicenter study 36
Atrial signal amplitude predicts atrial high-rate episodes in implantable cardioverter defibrillator patients: Insights from a large database of remote monitoring trasmissions 35
Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era 33
[Position paper of the Italian Society of Cardiology: The renin-angiotensin-aldosterone system (RAAS) blockade in heart failure patients - Part I: From RAAS identification to clinical trials] 30
Changes in Right Ventricular-to-Pulmonary Artery Coupling After Transcatheter Edge-to-Edge Repair in Secondary Mitral Regurgitation 29
Palliative care in the cardiac setting: A consensus document of the Italian Society of Cardiology (SIC) and Italian Society of Palliative Care (SICP) Joint Working Group 29
Implications of atrial fibrillation on the clinical course and outcomes of hospitalized COVID-19 patients: results of the Cardio-COVID-Italy multicentre study 28
A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization - the first insight from the AC-TIVE Study 28
Pulmonary embolism in patients with COVID-19: characteristics and outcomes in the Cardio-COVID Italy multicenter study 27
[Italian Society of Cardiology-Italian Society of Nephrology Consensus document: The cardio-renal interaction in the prevention and treatment of cardiovascular diseases - Part II: From preventive strategies to treatment of patients with cardio-renal damage] 25
[Position paper of the Italian Society of Cardiology: The renin-angiotensin-aldosterone system blockade in heart failure patients - Part II: Mechanistic effects of sacubitril/valsartan, placement in current guidelines and use in clinical practice] 24
Determinants of the protective effect of glucocorticoids on mortality in hospitalized patients with COVID-19: Insights from the Cardio-COVID-Italy multicenter study 23
The prognostic value of serial troponin measurements in patients admitted for COVID-19 23
[Transcatheter devices for chronic heart failure: state of the art] 22
Left ventricular wall thickness and severity of cardiac disease in women and men with transthyretin amyloidosis 22
[Rationale and significance of the Italian Network for Cardiac Amyloidosis] 21
Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy multicentre study 20
[Italian Society of Cardiology-Italian Society of Nephrology Consensus document: The cardio-renal interaction in the prevention and treatment of cardiovascular diseases - Part I: From cardiovascular risk factors to the mechanisms of cardio-renal syndrome] 19
Right ventricular to pulmonary artery coupling and outcome in patients with cardiac amyloidosis 19
Correction to: SARS‑CoV‑2, myocardial injury and inflammation: insights from a large clinical and autopsy study 17
[2022 Update on myocarditis and pericarditis following COVID-19 vaccination. Expert Opinion of the Italian Society of Cardiology] 16
Value of the HFA-PEFF and H2 FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis 16
Evolution of tricuspid regurgitation after transcatheter edge-to-edge mitral valve repair for secondary mitral regurgitation and its impact on mortality 16
[Italian Society of Cardiology (SIC) Position paper: Technical, instrumental and standards of interpretation for electrocardiography, ambulatory electrocardiographic and blood pressure monitoring in telemedicine] 16
Hepatic T1-time, cardiac structure and function and cardiovascular outcomes in patients with dilated cardiomyopathy 16
Performance of risk stratification scores and role of comorbidities in older vs younger patients with pulmonary arterial hypertension 14
Prognostic impact of the updated 2018 HFA-ESC definition of advanced heart failure: results from the HELP-HF registry 14
[Myocarditis and pericarditis following mRNA COVID-19 vaccination. Expert opinion of the Italian Society of Cardiology] 13
The impact of UEFA Euro 2020 football championship on Takotsubo Syndrome: Results of a multicenter national registry 13
Characteristics and outcomes of patients with tricuspid regurgitation and advanced heart failure 12
Ischemic Etiology in Advanced Heart Failure: Insight from the HELP-HF Registry 12
Effects of the COVID-19 pandemic on the formation of fellows in training in cardiology 11
SARS-CoV-2, myocardial injury and inflammation: insights from a large clinical and autopsy study 10
Clinical burden and predictors of non-cardiovascular mortality and morbidity in advanced heart failure 10
Detailed Assessment of the "I Need Help" Criteria in Patients With Heart Failure: Insights From the HELP-HF Registry 9
Outcome and Morphofunctional Changes on Cardiac Magnetic Resonance in Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination 9
[Italian Society of Cardiology (SIC) Expert consensus document: Post-acute cardiovascular sequelae of SARS-CoV-2 infection] 9
SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid Cardiomyopathy 8
ECG/echo indexes in the diagnostic approach to amyloid cardiomyopathy: A head-to-head comparison from the AC-TIVE study 8
Clinical and prognostic implications of heart failure hospitalization in patients with advanced heart failure 8
Frailty according to the 2019 HFA-ESC definition in patients at risk for advanced heart failure: Insights from the HELP-HF registry 8
Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC-TIVE study, an Italian nationwide survey 8
Prevalence and clinical outcomes of isolated or combined moderate to severe mitral and tricuspid regurgitation in patients with cardiac amyloidosis 7
Role of ejection fraction in patients at risk for advanced heart failure: insights from the HELP-HF registry 7
Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position Paper of the Italian Society of Cardiology 7
Glucagon-like peptide-1 receptor agonists use and associations with outcomes in heart failure and type 2 diabetes. Data from the Swedish Heart Failure and Swedish National Diabetes Registries 7
OPTImal PHARMacological therapy for patients with heart failure: Rationale and design of the OPTIPHARM-HF registry 6
Guideline-directed medical therapy in severe heart failure with reduced ejection fraction: an analysis from the HELP-HF registry 6
Apoptosis, a useful marker in the management of hot-phase cardiomyopathy? 5
Impact of malnutrition in patients with severe heart failure 5
Management of hypertrophic cardiomyopathy 4
Phenotype and outcomes according to loop diuretic use in pulmonary arterial hypertension 3
Frequency, characteristics and risk assessment of pulmonary arterial hypertension with a left heart disease phenotype 3
Totale 1.699
Categoria #
all - tutte 16.956
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.956


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020244 0 0 10 26 14 29 37 25 36 33 20 14
2020/2021204 12 10 19 21 15 18 3 28 16 31 16 15
2021/2022123 6 5 5 9 1 5 1 9 7 16 19 40
2022/2023238 37 23 4 4 11 52 2 23 51 3 14 14
2023/2024653 35 13 68 60 43 111 39 23 111 25 34 91
2024/202569 15 12 42 0 0 0 0 0 0 0 0 0
Totale 1.699